COMMUNIQUÉS West-GlobeNewswire

Sanofi and Regeneron Announce Approval of Dupixent® (dupilumab) to Treat Adult Patients with Moderate-to-Severe Atopic Dermatitis in the European Union

28/09/2017 - 07:00

Sanofi and Regeneron Announce Approval of Dupixent® (dupilumab) to Treat Adult Patients with Moderate-to-Severe Atopic Dermatitis in the European Union - First targeted biologic in the European Union to receive [...]

Sanofi et Regeneron annoncent l'approbation de Dupixent® (dupilumab) dans l'Union européenne pour le traitement de la dermatite atopique modérée à sévère de l'adulte

28/09/2017 - 07:00

Sanofi et Regeneron annoncent l'approbation de Dupixent ® (dupilumab) dans l'Union européenne pour le traitement de la dermatite atopique modérée à sévère de l'adulte - Premier médicament biologique ciblé à bénéficier d [...]

TiGenix to participate and present at key investor and business development meetings

28/09/2017 - 07:00

PRESS RELEASE TiGenix to participate and present at key investor and business development meetings Leuven (BELGIUM) - September 28, 2017, 07:00h CET - TiGenix NV (Euronext Brussels and NASDAQ: TIG), an advanced [...]

TiGenix participera à d'importantes réunions d'investisseurs et de développement d'affaires

28/09/2017 - 07:00

COMMUNIQUÉ DE PRESSE I TiGenix participera à d'importantes réunions d'investisseurs et de développement d'affaires Louvain (BELGIQUE) - 28 septembre 2017, 07h. CET - TiGenix NV (Euronext Brussels et NASDAQ : TIG), [...]

NuCana plc Announces Pricing of Initial Public Offering

28/09/2017 - 03:50

EDINBURGH, United Kingdom, Sept. 28, 2017 (GLOBE NEWSWIRE) -- NuCana plc (Nasdaq:NCNA), a clinical-stage biopharmaceutical company focused on significantly improving treatment outcomes for cancer patients by applying [...]

ProQR annonce les premiers résultats positifs d'une étude de Phase 1b de QR-010 chez des sujets atteints de mucoviscidose

28/09/2017 - 02:54

Principaux résultats Le QR-010 s'est révélé sûr et bien toléré pour toutes les doses de cet essai sans événements indésirables graves liés au traitement. Une amélioration cliniquement significative des symptômes [...]

Crown Bioscience nomme Laurie Heilmann à la direction des affaires commerciales ; ce cadre dirigeant apporte à cette fonction toute son expertise en matière de stratégie mondiale et de leadership c...

28/09/2017 - 02:30

SANTA CLARA, Californie, le 28 septembre 2017 (GLOBE NEWSWIRE) - Crown Bioscience , filiale en propriété exclusive de Crown Bioscience International (TWSE : code boursier 6554) et société internationale de services de [...]

ThromboGenics NV : ThromboGenics Presenting THR-687 Preclinical Data at European Association for Vision and Eye Research (EVER) Meeting

28/09/2017 - 00:05

Leuven, Belgium, 27 th September, 2017 - ThromboGenics NV (Euronext Brussels: THR), a biotechnology company developing novel treatments for retinal disorders, with a focus on diabetic eye disease, announced today that [...]

Bavarian Nordic Secures Contract Award for Supply of Freeze-dried IMVAMUNE Smallpox Vaccine to the U.S. Government

27/09/2017 - 22:17

Initial base award secures additional IMVAMUNE bulk contract of USD 100 million Contract includes initial options valued at USD 439 million Potential for contract value to increase if options to purchase additional [...]

Medtronic HeartWare(TM) HVAD(TM) System Approved for Destination Therapy

27/09/2017 - 22:05

Patients with End-Stage Heart Failure Now Have New Options for Care DUBLIN - September 27, 2017 - Medtronic plc (NYSE: MDT) has received U.S. Food and Drug Administration (FDA) approval for its HeartWare(TM) HVAD(TM) [...]

New Center for Kinesio Taping Methods opens at the University of New Mexico

27/09/2017 - 21:19

Albuquerque, New Mexico, Sept. 27, 2017 (GLOBE NEWSWIRE) -- On Tuesday September 26, 2017, the University of New Mexico School of Medicine Department of Neurosurgery and Kinesio began their Educational Collaborative [...]

The Finnish Financial Supervisory Authority approved Terveystalo Plc's Finnish language prospectus

27/09/2017 - 18:00

TERVEYSTALO PLC September 27, 2017 at 19:00 pm EET NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, CANADA, THE HONG KONG SPECIAL ADMINISTRATIVE REGION OF [...]

Crown Bioscience Names Laurie Heilmann Chief Business Officer; Executive Leader Brings Expertise in Global Strategy and Commercial Leadership to the Role

27/09/2017 - 14:00

SANTA CLARA, Calif., Sept. 27, 2017 (GLOBE NEWSWIRE) -- Crown Bioscience , a wholly-owned subsidiary of Crown Bioscience International (TWSE:ticker 6554) and a global drug discovery and development services company [...]

Inivata: Addario Lung Cancer Medical Research Institute and Inivata Announce Major Study of ctDNA Analysis in Early Stage Lung Cancer

27/09/2017 - 13:30

Addario Lung Cancer Medical Research Institute and Inivata Announce Major Study of ctDNA Analysis in Early Stage Lung Cancer InVision(TM) ctDNA liquid biopsy platform to be used to inform therapy following surgery of [...]

Terveystalo announces a fixed subscription price for its contemplated initial public offering and further information on the listing of its shares on the Official List of Nasdaq Helsinki Ltd

27/09/2017 - 10:30

TERVEYSTALO PLC September 27, 2017 at 11:30 am EET NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, CANADA, THE HONG KONG SPECIAL ADMINISTRATIVE REGION OF [...]

Ossur Hf : Össur Capital Markets Day 27 September 2017 presentation material

27/09/2017 - 08:15

Enclosed is the presentation material ahead of Össur's Capital Markets Day 2017 which is held today from 8:30 - 13:00 CET in Copenhagen. Össur Capital Markets Day 27 September 2017 This announcement is distributed by [...]

Herantis Pharma has initiated patient recruitment and consented first patient in CDNF study in Parkinson's disease

27/09/2017 - 08:00

Herantis Pharma has initiated patient recruitment and consented first patient in CDNF study in Parkinson's disease Herantis Pharma Plc Company release 27 Sep 2017 at 9:00 am Herantis Pharma Plc ("Herantis") has [...]

Verona Pharma Reports Positive Top-Line Data from U.S. Pharmacokinetic Trial Demonstrating Nebulized RPL554 Delivers Optimal Clinical Dose to Patients

27/09/2017 - 08:00

Earlier than expected results demonstrate absorption occurs primarily in the lungs following inhaled administration LONDON, Sept. 27, 2017 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) (NASDAQ:VRNA) ("Verona Pharma [...]

Galapagos and MorphoSys report first promising signs of clinical activity in a Phase 1 study with IL-17C antibody MOR106 in atopic dermatitis patients

27/09/2017 - 07:30

Generally well-tolerated with no clinically relevant safety signals in Phase 1 study At the highest dose level, 5 out of 6 patients (83%) reached an improvement of at least 50% in atopic dermatitis symptoms (EASI-50) by [...]